These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38141462)

  • 1. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
    Cantini L; Trapani D; Guidi L; Boscolo Bielo L; Scafetta R; Koziej M; Vidal L; Saini KS; Curigliano G
    Cancer Treat Rev; 2024 Feb; 123():102669. PubMed ID: 38141462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
    Hofmann D; Nitz U; Gluz O; Kates RE; Schinkoethe T; Staib P; Harbeck N
    Trials; 2013 Aug; 14():261. PubMed ID: 23958221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
    Garufi G; Carbognin L; Arcanà C; Parola S; Ventriglia A; Doronzo A; Garutti M; Orlandi A; Palazzo A; Fabi A; Bria E; Tortora G; Arpino G; Giuliano M; Del Mastro L; De Laurentiis M; Puglisi F
    Cancer Treat Rev; 2022 Nov; 110():102454. PubMed ID: 35987149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
    Schettini F; Nucera S; Brasó-Maristany F; De Santo I; Pascual T; Bergamino M; Galván P; Conte B; Seguí E; García Fructuoso I; Gómez Bravo R; Rivera P; Rodríguez AB; Martínez-Sáez O; Ganau S; Sanfeliu E; González-Farre B; Vidal Losada MJ; Adamo B; Cebrecos I; Mension E; Oses G; Jares P; Vidal-Sicart S; Mollà M; Muñoz M; Prat A
    ESMO Open; 2024 Jul; 9(7):103619. PubMed ID: 38943737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.
    Sirico M; Virga A; Conte B; Urbini M; Ulivi P; Gianni C; Merloni F; Palleschi M; Gasperoni M; Curcio A; Saha D; Buono G; Muñoz M; De Giorgi U; Schettini F
    Crit Rev Oncol Hematol; 2023 Jan; 181():103900. PubMed ID: 36565894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers.
    Ortmann O; Blohmer JU; Sibert NT; Brucker S; Janni W; Wöckel A; Scharl A; Dieng S; Ferencz J; Inwald EC; Wesselmann S; Kowalski C;
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1195-1209. PubMed ID: 35380257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
    Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis.
    Liu M; Xiang Q; Dai F; Yuan Y; Wu Z; Xiang T
    Clin Breast Cancer; 2024 Oct; 24(7):575-584.e1. PubMed ID: 38821742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
    Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
    Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
    Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
    Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
    Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
    Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S;
    JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.